A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

NCT06659341 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors Harboring KRAS G12C Mutation

Interventions

DRUG: BAY3498264

Sponsor

Bayer